Skip to main content
Equibles
BHC logo

BHC · Bausch Health Companies Inc. · Metrics

Track BHC — free

Use BHC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BHC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$8.63 +1.71 (+24.64%) Q3 2026 earnings call transcript
Rebalance outlook locked
Market Cap
$2.59B
Shares
373.99M
Volume · Oct 29 13.17M Avg daily vol (3M) 3.35M

BHC metrics

98 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$6.92
Market cap
$2.59B

Price action

20 metrics
Price change (1W)
+7.3%
Price change (30D)
+19.3%
Price change (3M)
+47.9%
Price change (6M)
+23.8%
Price change (YTD)
-0.4%
Price change (1Y)
+11.8%
Trailing year
Price change (5Y)
-74.9%
52-week high
$7.90
52-week low
$4.43
Change from 52-week high
-12.4%
Change from 52-week low
+56.2%
Annualized volatility
57.0%
Annualized volatility (3M)
78.2%
Beta
0.9
RSI (14D)
72.4
Price vs SMA 50
+12.2%
Price vs SMA 200
+21.6%
Avg volume (3M)
3.35M
Relative volume
2.4
Average dollar volume
$21.23M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
373.99M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
2.0×
reciprocal yield 50.5%
EV / EBITDA
10.5×
reciprocal yield 9.6%
EV / EBIT
24.4×
reciprocal yield 4.1%
P / sales
0.2×
reciprocal yield 419.4%
P / book
—
FCF yield
55.3%
TTM · current market cap
Buyback yield
—
P / FCF
1.8
reciprocal yield 55.3%
P / operating cash flow
1.4
reciprocal yield 69.6%
Earnings yield
-42.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
18.1×
reciprocal yield 5.5%
EV / revenue historical average (3Y)
2.4×
reciprocal yield 41.2%
EV / revenue historical average (5Y)
2.7×
reciprocal yield 36.9%
EV / EBIT historical average (3Y)
24.8×
reciprocal yield 4.0%
EV / EBIT historical average (5Y)
48.4×
reciprocal yield 2.1%
EV / EBITDA historical average (3Y)
10.2×
reciprocal yield 9.8%
EV / EBITDA historical average (5Y)
11.3×
reciprocal yield 8.9%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-28

Profitability

9 metrics
Gross margin
—
Operating margin
8.1%
Trailing 12 months
Net margin
-10.1%
Gross profit (TTM)
$6.07B
Operating profit (TTM)
$883.00M
Net income (TTM)
−$1.10B
Trailing 12 months
Diluted EPS (TTM)
$-2.96
FCF margin
13.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$28.78
Gross profit per diluted share (TTM)
$17.25
Operating profit per diluted share (TTM)
$2.30
EBITDA per diluted share (TTM)
$5.41
Net income per diluted share (TTM)
$-2.95
Operating cash flow per diluted share (TTM)
$4.76
Free cash flow per diluted share (TTM)
$3.79
Capital expenditures per diluted share (TTM)
$0.98
R&D per diluted share (TTM)
$1.76
Stock compensation per diluted share (TTM)
$0.62
Book value per share
$-1.50

Growth

11 metrics
Revenue growth YoY
+12.7%
Year over year
Net income growth YoY
+74.3%
Revenue (TTM)
$10.85B
Trailing 12 months
EPS growth YoY
+70.0%
Shares change YoY
+1.3%
Year over year · more shares
Revenue CAGR (3Y)
+8.1%
Revenue CAGR (5Y)
+5.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
+4.4%

Quality

14 metrics
Return on equity
—
Return on assets
-4.4%
Debt / equity
—
Current ratio
1.4
EBITDA (TTM)
$2.06B
Free cash flow (TTM)
$1.43B
Quick ratio
1.1
Interest coverage
—
Net debt / EBITDA
9.2
Return on invested capital
—
Trailing 12 months
Net cash
−$18.92B
Latest balance sheet
Cash & equivalents
$1.82B
Total assets
$24.79B
Total debt
$20.74B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$1.80B
Capital expenditures (TTM)
$369.00M
R&D (TTM)
$663.00M
SG&A (TTM)
$3.44B
Stock compensation (TTM)
$233.00M
R&D / revenue
6.1%
Stock compensation / revenue
2.1%

Ownership (13F)

9 metrics
13F filers
224
13F filer change QoQ
-8
Institutional ownership
66.9%
Conviction holders (share of 13F filers)
2.3%
Crowding (high-turnover and private-fund holders)
19.9%
Private-fund adviser ownership
18.8%
Active holders' share change QoQ
+1.1%
Holder tenure
20.2
Price vs estimated holder cost
-35.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
3.1%

Short interest

3 metrics
Short interest
2.2%
Latest settlement · 4.2 days to cover
Days to cover
4.2d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$258,894
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 885590 CUSIP 071734107 13F (30d) 46 filings 38 filers Visit website Investor relations